Ophthotech (Fovista ex-US rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Ophthotech (Fovista ex-US rights) General Information

Description

Rights of a eye drug Fovista of Ophthotech. The drug is used to treat diseases of the eye, with a particular focus on diseases of the back of the eye. It is an anti platelet-derived growth factor (anti-PDGF) agent in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in the eye.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • One Penn Plaza
  • Suite 1924
  • New York, NY 10119
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Novartis
Corporate Office
  • One Penn Plaza
  • Suite 1924
  • New York, NY 10119
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ophthotech (Fovista ex-US rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ophthotech (Fovista ex-US rights)‘s full profile, request access.

Request a free trial

Ophthotech (Fovista ex-US rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ophthotech (Fovista ex-US rights)‘s full profile, request access.

Request a free trial

Ophthotech (Fovista ex-US rights) FAQs

  • Where is Ophthotech (Fovista ex-US rights) headquartered?

    Ophthotech (Fovista ex-US rights) is headquartered in New York, NY.

  • What industry is Ophthotech (Fovista ex-US rights) in?

    Ophthotech (Fovista ex-US rights)’s primary industry is Buildings and Property.

  • Is Ophthotech (Fovista ex-US rights) a private or public company?

    Ophthotech (Fovista ex-US rights) is a Private company.

  • What is the current valuation of Ophthotech (Fovista ex-US rights)?

    The current valuation of Ophthotech (Fovista ex-US rights) is .

  • What is Ophthotech (Fovista ex-US rights)’s current revenue?

    The current revenue for Ophthotech (Fovista ex-US rights) is .

  • Who are Ophthotech (Fovista ex-US rights)’s investors?

    IVERIC bio has invested in Ophthotech (Fovista ex-US rights).

  • When was Ophthotech (Fovista ex-US rights) acquired?

    Ophthotech (Fovista ex-US rights) was acquired on 20-May-2014.

  • Who acquired Ophthotech (Fovista ex-US rights)?

    Ophthotech (Fovista ex-US rights) was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »